Drug Profile
Grass pollen allergy immunotherapy low dose - ALK-Abello
Alternative Names: Avanz; Grass pollen allergy vaccine - ALK-AbelloLatest Information Update: 01 Feb 2016
Price :
$50
*
At a glance
- Originator ALK-Abello
- Class Allergens; Antiallergics; Plant allergy immunotherapies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Allergic rhinoconjunctivitis
Most Recent Events
- 01 Oct 2015 ALK-Abelló completes a phase II trial in Allergic rhinoconjunctivitis in Germany (NCT02166268)
- 24 Apr 2012 ALK-Abelló completes a phase II/III trial in Allergic rhinoconjunctivitis in Spain (NCT01454531)
- 10 Feb 2012 ALK-Abelló completes enrolment in its phase II/III trial for Allergic rhinoconjunctivitis in Austria, Germany and Spain (NCT01438827)